J&J Expects Sales Loss To Be Skin-Deep, Looks To Skin-Care Lines For Boost
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson looks to rebound from its first yearly decline in sales since the Depression in part by capitalizing on momentum in its skin-care business with extensions of its Aveeno, Neutrogena and RoC lines designed to meet anti-aging needs around the clock
You may also be interested in...
McNeil Expands Tylenol Recall As FDA Criticizes Firm's Response To AERs
McNeil Consumer Healthcare's reaction to signs of potentially contaminated packaging for OTC products including Tylenol raised FDA's ire and is now costing the firm an extensive product recall
J&J Ready To Capitalize On Zyrtec OTC Launch As Allergy Drug Hits Shelves
Johnson & Johnson's consumer product business is positioned to capitalize on the launch of nonprescription Zyrtec (cetirizine HCl) allergy medicine, J&J CEO Bill Weldon said during the firm's year-end analyst meeting Jan. 22
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC